624-P: Effects of Semaglutide Treatment on Dietary Behavior in Japanese Patients with Type 2 Diabetes Mellitus

Abstract

Objective and Methods: Eating behavior questionnaire issued by the Japan Society for the Study of Obesity was administered to 41 patients who received semaglutide injection (SI) and 52 patients who received oral semaglutide (OS) in our outpatient clinic. Changes in HbA1c levels, body weight, eating behavior, and their correlations after 3 months of treatment were examined. Results: The mean dose after 3 months of treatment was 0.50 ± 0.17 mg/week in the SI group and 6.35 ± 2.29 mg/day in the OS group. Mean HbA1c significantly decreased from 7.34 ± 0.97% to 6.85 ± 0.72% in the SI group and from 7.65 ± 0.94% to 7.± 0.91% in the OS group (p<0.001) . Weight significantly decreased from 79.1 ± 16.3 kg to 76.8 ± 16.8 kg in the SI group and from 74.8 ± 15.2 kg to 73.2 ± 15.4 kg in the OS group (p<0.001) . In the SI group, “Recognition for weight and constitution,” “External eating behavior,” “Sense of hunger,” “Eating style,” “Food preference,” “Regularity of eating habit” and the total scores of the questionnaire significantly improved after 3 months, while in the OS group, all factors improved significantly. In the SI group, there was a significant positive correlation between the changes in HbA1c level over 3 months and the changes in scores for “Regularity of eating habit” (r=0.401, p=0.013) and between the changes in weight and the changes in total scores (r=0.330, p=0.043) . In the OS group, the changes in weight was significantly and positively correlated with the changes in scores for “External eating behavior,” “Emotional eating behavior,” “Sense of hunger,” and “Regularity of eating habit,” and the changes in total scores. Adverse events were nausea (22.6%) , diarrhea (14.0%) , constipation and stomach pain (5.4% each) , fatigue (3.2%) , abdominal distension (2.2%) , soft stool, abdominal pain, and headache (1.1% each) in the total. Conclusion: These results suggest that semaglutide improves glycemic control and eating behavior in Japanese patients with type 2 diabetes. Disclosure S.T.Sato: None. H.Kamiya: Research Support; Abbott Japan Co., Ltd., Eli Lilly and Company, Japan Tobacco Inc., Kissei Pharmaceutical Co., Ltd., Kowa Company, Ltd., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk, Ono Pharmaceutical Co., Ltd., Sanwa Kagaku Kenkyusho, Sumitomo Dainippon Pharma Co., Ltd., Taiho Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Terumo Corporation, Speaker's Bureau; Astellas Pharma Inc., AstraZeneca, Boehringer Ingelheim International GmbH, Daiichi Sankyo, Eli Lilly and Company, Kissei Pharmaceutical Co., Ltd., Kowa Company, Ltd., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K., Novo Nordisk, Ono Pharmaceutical Co., Ltd., Sanofi K.K., Sanwa Kagaku Kenkyusho, Sumitomo Dainippon Pharma Co., Ltd., Taisho Pharmaceutical Holdings Co., Ltd. T.Tosaki: Other Relationship; Eli Lilly and Company, Novo Nordisk, Sumitomo Dainippon Pharma Co., Ltd. A.Kotorii: None. M.Kondo: n/a. E.Miura-yura: None. S.Tsunekawa: n/a. T.Himeno: None. Y.Kato: None. J.Nakamura: None.